Le Blanc Katarina, Ringdén Olle
Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, F79, SE-141 86 Stockholm, Sweden.
Curr Opin Immunol. 2006 Oct;18(5):586-91. doi: 10.1016/j.coi.2006.07.004. Epub 2006 Aug 1.
Mesenchymal stem cells (MSCs) can be isolated from bone marrow, adipose tissue, cord blood and various fetal tissues. They have the capacity to differentiate into several tissues, including bone, cartilage, tendon, muscle and adipose, and produce growth factors and cytokines that promote hematopoietic cell expansion and differentiation. MSCs also have anti-proliferative, immunomodulatory and anti-inflammatory effects, but only evoke little immune reactivity. In vivo, MSCs prolong skin allograft survival and reverse severe acute graft-versus-host disease. Furthermore, they repair damaged tissue from kidney, heart, liver and gastrointestinal tract. Therefore, in the future, MSCs might have implications for treatment of allograft rejection, graft-versus-host disease, autoimmune inflammatory bowel disease and other disorders in which immunomodulation and tissue repair are required.
间充质干细胞(MSCs)可从骨髓、脂肪组织、脐带血和各种胎儿组织中分离出来。它们有能力分化为多种组织,包括骨、软骨、肌腱、肌肉和脂肪,并产生促进造血细胞扩增和分化的生长因子和细胞因子。间充质干细胞还具有抗增殖、免疫调节和抗炎作用,但仅引起极少的免疫反应。在体内,间充质干细胞可延长皮肤同种异体移植的存活时间,并逆转严重的急性移植物抗宿主病。此外,它们还能修复肾脏、心脏、肝脏和胃肠道的受损组织。因此,在未来,间充质干细胞可能对治疗同种异体移植排斥反应、移植物抗宿主病、自身免疫性炎症性肠病以及其他需要免疫调节和组织修复的疾病具有重要意义。